Indian drugmaker Ranbaxy Laboratories says it will acquire stakes in two as yet unidentified companies, in order to establish marketing alliances with those firms. Ranbaxy added that its aim is to use a worldwide marketing network to source products through collaborations in regions where it does not have a significant presence. The firm added that it has also acquired a 10% holding in fellow Indian company Zenotech and has agreed a marketing venture to commercialize the latter's injectable oncology products for international markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze